GRP and neoplasm: While Demobesin 1 acted as a potent antagonist, reversing the stimulatory effects of gastrin-releasing peptide (GRP) substrates, Demobesin 4 demonstrated higher internalization in HEK293 and PC3 cell lines, showcasing its potential as a tumor-targeting agent [89].